www.lilly.co.uk

Eli Lilly and Company Limited
Lilly House
Priestley Road
Basingstoke
Hampshire
RG24 9NL

Tel: +44 (0) 1256 315000

HTA and Health Outcomes

Medical and Product Information: +44 (0) 1256 315999

17th March 2014

Meindert Boysen
Programme Director, Technology Appraisals
Centre for Health Technology Evaluation
National Institute for Health and Care Excellence
1st Floor
10 Spring Gardens
London
SW1A 2BU

Dear Meindert

Diabetes (type 2) – canagliflozin [ID554]:
Eli Lilly and Company Ltd response to Appraisal Consultation Document (ACD) consultation

Thank you for the opportunity to review and respond to the Appraisal Consultation Document (ACD) for canagliflozin in combination therapy for treating type 2 diabetes.

Eli Lilly supports the development of new technologies which provide individual treatment choices and a patient-centred approach to diabetes management.

With regard to the specific questions posed in the ACD, we have no comments to make.

Yours sincerely,

[redacted]
Head of HTA/HO – Lilly UK